A tool to help your doctors diagnose and plan the treatment of neuroendocrine tumors (NETs)
NETSPOT®, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Why are you having a PET scan?
If you’ve been diagnosed with a neuroendocrine tumor (NET) or your doctor is concerned that you may have this type of disease, you may be asked to undergo a positron emission tomography (PET) scan. A PET scan helps your doctor locate, stage, and identify the extent of disease in order to diagnose and manage your condition.
Somatostatin is a hormone important in regulating the endocrine system through its interaction with other hormones, including most of those in the gastrointestinal tract. Somatostatin binds to somatostatin receptors (SSTRs), which are characteristically overexpressed by NETs. NETSPOT® is a radioactive product that binds to SSTRs, hereby highlighting NETs on PET scan images to help your doctors assess your disease and plan the most effective treatment.
Before your procedure
Be sure to tell your doctor about any medications you are taking, including:
Prescription and over-the-counter medications.
Herbal medications and vitamins Somatostatin analogs, like octreotide or lanreotide, bind to the same SSTRs as NETSPOT®.
Your doctor will schedule your NETSPOT® scan just prior to your next dose of long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before a NETSPOT®
It is important to stay hydrated. Drink plenty of water prior to your PET scan appointment.
Following the injection of NETSPOT®, you will be asked to wait 40 to 90 minutes before a PET scan can be performed. The PET scan will take an additional 30 to 60 minutes. You will be asked to lie still during the PET scan, as movement can negatively affect the quality of the images taken during the scan. You will not receive results immediately after your scan. Your healthcare provider will follow up with you after the images have been assessed by an appropriate medical professional.
Following your procedure
Reduce radiation exposure Continue to drink lots of water, and urinate as frequently as possible during the first hours following your scan. This will help clear NETSPOT® from your body and reduce radiation exposure.
Contact with others
Close contact with infants and pregnant women should be restricted during the first 8 hours after your procedure.
Nursing mothers should substitute stored breast milk or infant formula for breast milk for 12 hours following the administration of NETSPOT®. Call your doctor or pharmacist if you develop any unusual symptoms, or if any known symptom persists or worsens.
The level of radiation you are exposed to with NETSPOT® is very low—less than the average annual exposure from radiation in the atmosphere.3 There are usually no notable side effects following injection of NETSPOT®. However, because NETSPOT® is a radioactive solution, there are some steps you should take to reduce your radiation exposure and prevent potential exposure to others.
NETSPOT® will expose you to ionizing radiation. Your doctor will have determined that the likely diagnostic benefit is greater than the risks. If you have concerns about NETSPOT®, talk to your healthcare providers about the risks and expected benefits.
If there is a possibility of pregnancy, you should not use NETSPOT®. Talk to your doctor if you think you may be pregnant or are likely to become pregnant. You should avoid direct contact with infants or pregnant women during the first 8 hours after your healthcare provider has administered NETSPOT®.
Getting to your appointment
NETSPOT® will not change the way you feel. There is no evidence that NETSPOT® impairs your ability to drive, so you do not necessarily need anyone to accompany you to your appointment.
Warnings and Precautions
Ga 68 dotatate contributes to your overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer.